Results 11 to 20 of about 4,368 (233)

Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis. [PDF]

Endocr Connect
Purpose The aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally.
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson MO, Dassie F, Prencipe N, Ragonese M, Gomez R, Granato S, Cannavò S, Grottoli S, Maffei P, Colao A, Bogazzi F, Bianchi A.   +15 more
europepmc   +4 more sources

Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome. [PDF]

JCEM Case Rep
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare genetic disorder resulting from a postzygotic activating mutation of the GNAS gene, leading to mosaic activation of the Gs protein. FD/MAS encompasses skeletal and extraskeletal manifestations,
Tan JY, Chemmanam J, Burt MG, Nguyen HTT, Ho JT.   +4 more
europepmc   +4 more sources

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Frontiers in Oncology, 2022
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. Therefore,
Ahmed O. Kaseb, Abedul Haque, Deeksha Vishwamitra, Manal M. Hassan, Lianchun Xiao, Bhawana George, Vishal Sahu, Yehia I. Mohamed, Roberto Carmagnani Pestana, Jamie Lynne Lombardo, Rony Avritscher, James C. Yao, Robert A. Wolff, Asif Rashid, Jeffrey S. Morris, Hesham M. Amin, Hesham M. Amin   +16 more
doaj   +2 more sources

Pegvisomant: uso clínico en pacientes con acromegalia

Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2022
Contexto: el manejo de los pacientes con acromegalia actualmente incluye cirugía, radioterapia y terapia farmacológica. Aunque la cirugía es el tratamiento de primera línea, un gran porcentaje de pacientes van a requerir manejo adicional con ...
Alejandro Román-González, Huber Padilla-Zambrano, Carlos Alfonso Builes-Barrera, Henry Tovar   +3 more
doaj   +2 more sources

Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)

Ожирение и метаболизм, 2019
This review provides the main results of clinical trials and the literature on the experience of using pegvisomant, the first drug from the class of growth hormone receptor antagonists.
Larisa K. Dzeranova, Alexandra A. Povaliaeva, Anastasia A. Romanova, Elena G. Przhiyalkovskaya, Ekaterina A. Pigarova, Natalia S. Fedorova   +5 more
doaj   +3 more sources

Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity [PDF]

Frontiers in Endocrinology
Recombinant human IGF-1 is used to treat severe primary IGF-1 deficiency, but this treatment requires twice-daily injection, often does not fully correct the growth deficit, and has important off-target effects.
Krishma Tailor, Krishma Tailor, Janine van Ree, Timothy Stowe, Brit Ventura, Connor Sisk, Joanna Courtis, Anna Camp, Fatima Elzamzami, Jan van Deursen, Robert O’Brien, Jeffrey Baron, Julian C. Lui   +12 more
doaj   +2 more sources

Pegvisomant in the treatment of acromegaly [PDF]

Vnitrni lekarstvi, 2022
Despite improvements in surgical techniques, current radiotherapy options and development of long-acting somatostatin analogues, biochemical control of acromegaly is not achieved in some patients.
Ivana Ságová, Marian Mokáň, Juraj Payer, Peter Vaňuga   +3 more
openalex   +2 more sources

Brazilian multicenter study on pegvisomant treatment in acromegaly

Archives of Endocrinology and Metabolism, 2019
Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just ...
Cesar L. Boguszewski, Martha Katherine P Huayllas, Lucio Vilar, Luciana Ansaneli Naves, Antonio Ribeiro-Oliveira Junior, Beatriz Santana Soares, Mauro Antonio Czepielewski, Julio Abucham, Silvia Regina Correa-Silva, Marcello Delano Bronstein, Raquel Soares Jallad, Felipe Gaia Duarte, Nina Rosa Musolino, Leandro Kasuki, Monica Roberto Gadelha   +14 more
doaj   +2 more sources

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY [PDF]

Journal of Endocrinological Investigation, 2022
A comprehensive picture of pegvisomant use for treating acromegaly in routine clinical practice in different countries is lacking. We aimed, therefore, to document country-specific behaviors in real-life pegvisomant use, and the main safety and ...
Silvia Grottoli, Antonio Bianchi, Fausto Bogazzi, Chiara Bona, Martin Carlsson, Annamaria Colao, Francesca Dassie, Antonella Giampietro, Roy Gomez, S. Granato, Pietro Maffei, Rosario Pivonello, Nunzia Prencipe, M. Ragonese, Claudio Urbani, Salvatore Cannavò   +15 more
openalex   +2 more sources

Growth hormone receptor antagonists, GHA2 and GHA3, with dual activity against the human and mouse receptor. [PDF]

Protein Sci
Abstract Aberrant human growth hormone (GH) expression has been increasingly linked to poor outcomes in certain cancers and reduced health span. GH receptor (GHR) signal transduction activates signaling pathways that promote cell proliferation and survival, contributing to tumor progression.
Wang Y, Langley RJ, Harms J, Portlock T, Jamieson SMF, Perry JK.   +5 more
europepmc   +2 more sources